- Home
- YYGH vs ALRN Comparison
YYGH vs ALRN Comparison
Compare YYGH & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYGH
- ALRN
- Stock Information
- Founded
- YYGH 2010
- ALRN 2001
- Country
- YYGH Singapore
- ALRN United States
- Employees
- YYGH N/A
- ALRN N/A
- Industry
- YYGH
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- YYGH
- ALRN Health Care
- Exchange
- YYGH NYSE
- ALRN Nasdaq
- Market Cap
- YYGH 68.0M
- ALRN 76.9M
- IPO Year
- YYGH 2024
- ALRN 2017
- Fundamental
- Price
- YYGH $1.98
- ALRN $1.86
- Analyst Decision
- YYGH
- ALRN Strong Buy
- Analyst Count
- YYGH 0
- ALRN 1
- Target Price
- YYGH N/A
- ALRN $19.00
- AVG Volume (30 Days)
- YYGH 32.1K
- ALRN 92.8K
- Earning Date
- YYGH 02-15-2025
- ALRN 11-14-2024
- Dividend Yield
- YYGH N/A
- ALRN N/A
- EPS Growth
- YYGH 527.44
- ALRN N/A
- EPS
- YYGH 0.04
- ALRN N/A
- Revenue
- YYGH $37,372,731.00
- ALRN N/A
- Revenue This Year
- YYGH N/A
- ALRN N/A
- Revenue Next Year
- YYGH N/A
- ALRN N/A
- P/E Ratio
- YYGH $48.51
- ALRN N/A
- Revenue Growth
- YYGH 55.18
- ALRN N/A
- 52 Week Low
- YYGH $0.72
- ALRN $1.61
- 52 Week High
- YYGH $4.70
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- YYGH N/A
- ALRN 36.91
- Support Level
- YYGH N/A
- ALRN $1.86
- Resistance Level
- YYGH N/A
- ALRN $2.38
- Average True Range (ATR)
- YYGH 0.00
- ALRN 0.30
- MACD
- YYGH 0.00
- ALRN -0.00
- Stochastic Oscillator
- YYGH 0.00
- ALRN 23.42
About YYGH YY GROUP HOLDING LIMITED
YY Group Holding Ltd is a data and technology driven company focused on developing enterprise intelligent labor matching services and smart cleaning services founded in Singapore. It provides enterprise manpower outsourcing and smart cleaning services in Singapore and Malaysia. The group has two operating segment, which is cleaning services segment and manpower outsourcing services, Maximum revenue is generated from cleaning services.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.